Literature DB >> 2883745

Engraftment following T-cell-depleted marrow transplantation. I. The role of major and minor histocompatibility barriers.

J Ferrara, J Lipton, S Hellman, S Burakoff, P Mauch.   

Abstract

These experiments describe a murine model for survival and engraftment of bone marrow transplantation across differing histocompatibility barriers. Anti-Thy-1.2 antibody and complement-treated C57BL/6 (B6) marrow was transplanted at varying cell dose levels into syngeneic (B6), major histocompatibility complex congenic (A.BY), semiallogeneic (B6AF1), and fully allogeneic (A/J) recipients. Survival was monitored and engraftment determined by hemoglobin and lymphocyte phenotype. Survival was cell-dose dependent and was equivalent in B6, A.BY, and B6AF1 recipients. Survival was poor in allogeneic A/J recipients due to bone marrow failure even at high marrow dose levels. Survival posttransplant did not always correlate with stable donor engraftment, and competitive host marrow repopulation was frequently seen in B6AF1 recipients but rarely in A.BY recipients. This repopulation could be prevented by transplanting a larger marrow dose.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2883745     DOI: 10.1097/00007890-198704000-00001

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  Short-term medical consequences of the chernobyl nuclear accident: lessons for the future.

Authors:  R P Gale
Journal:  Can Fam Physician       Date:  1988-11       Impact factor: 3.275

Review 2.  Bone marrow transplantation: the genetic and cellular basis of resistance to engraftment and acute graft-versus-host disease.

Authors:  J Ferrara; P Mauch; G Murphy; S J Burakoff
Journal:  Surv Immunol Res       Date:  1985

3.  Induction of donor-specific transplantation tolerance to skin and cardiac allografts using mixed chimerism in (A + B-->A) in rats.

Authors:  P M Markus; G Selvaggi; X Cai; J J Fung; T E Starzl
Journal:  Cell Transplant       Date:  1993 Jul-Aug       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.